Anti Nmda Receptor Encephalitis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Anti-NMDA Receptor Encephalitis (NMDARE) is an autoimmune neurological disorder characterized by antibodies targeting the N-methyl-D-aspartate (NMDA) type of glutamate receptors in the brain. It is the most common form of autoimmune encephalitis and represents a paradigmatic example of antibody-mediated neuronal dysfunction[1][2].
Anti-NMDA Receptor Encephalitis was first described in 2007 by Dr. Josep Dalmau and colleagues as a paraneoplastic disorder associated with ovarian teratomas[1:1]. The condition has since been recognized as one of the most frequent autoimmune encephalitides, affecting individuals of all ages with a predominance in young women[2:1][3].
The disease involves immune-mediated dysfunction of NMDA receptors, which are critical for synaptic plasticity, learning, and memory. Understanding this condition is essential for neurologists, psychiatrists, and neuroscientists studying neurodegenerative processes[4].
The pathogenic autoantibodies in Anti-NMDA Receptor Encephalitis target the GluN1 (NR1) subunit of the NMDA receptor[1:2]. These antibodies are typically IgG antibodies that recognize epitopes on the extracellular domain of the receptor, leading to receptor internalization and functional downregulation[5].
The immune response in NMDARE involves:
Approximately 30-50% of cases are associated with tumors, most commonly[1:3][2:4]:
The tumor expression of NMDA receptor antigens triggers cross-reactive antibody production[1:4].
Many patients experience a prodromal phase lasting days to weeks with[2:5]:
Clinical diagnosis is based on the presence of[2:8]:
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Plasma Exchange
Tumor Removal
For patients with inadequate response to first-line therapy[3:5][7]:
Rituximab (anti-CD20)
Cyclophosphamide
Azathioprine or Mycophenolate
Favorable:
Unfavorable:
While primarily an autoimmune condition, Anti-NMDA Receptor Encephalitis provides insights into[4:1][5:2]:
The study of Anti Nmda Receptor Encephalitis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098. PMID:18851928 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74. PMID:21163445 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165. PMID:23290630 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866-5875. PMID:20427647 ↩︎ ↩︎
Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl-D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138(Pt 1):94-109. PMID:25414356 ↩︎ ↩︎ ↩︎
Probasco JC, Solnes L, Nalluri A, et al. Decreased occipital lobe metabolism by FDG-PET in anti-NMDA receptor encephalitis: a potential biomarker. J Neurol Neurosurg Psychiatry. 2018;89(5):526-532. PMID:29097675 ↩︎ ↩︎
Lee WJ, Lee ST, Byun JI, et al. Rituximab treatment for autoimmune encephalitis: a systematic review. J Clin Neurol. 2020;16(2):235-244. PMID:32265241 ↩︎
Gabilondo I, Saiz A, Galán L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011;77(10):996-999. PMID:21878623 ↩︎